The research team, working under PRISMA guidelines, searched MEDLINE, the Cochrane Library, and two Japanese databases, screening 299 articles down to eight eligible case series published between 2019 and 2022. Together, these studies covered 208 patients, nearly all treated in Japan, with one Dutch cohort. All participants had initially unresectable, locally advanced esophageal squamous cell carcinoma and received radiation doses between 50.4 and 60 Gy before undergoing salvage surgery. The authors assessed study quality with the Joanna Briggs Institute checklist and pooled outcomes using single-proportion meta-analysis with the Freeman–Tukey transformation. Because every included study was a case series, the overall evidence level was rated at four on the Oxford scale—weak by design, but for many of these patients it is the only evidence that exists.

The headline numbers are striking. Across the pooled cohort, 30 percent of patients experienced serious postoperative complications of Clavien–Dindo grade III or higher. Anastomotic leaks—the breakdown of the surgical connection between the remaining esophagus or stomach and the digestive tract—occurred in 18 percent of cases. Pulmonary complications, including pneumonia, pleural effusion, and acute respiratory distress syndrome, affected 31 percent of patients, making breathing problems the most common burden after these operations. Postoperative mortality, defined variously across studies as 30-day, 90-day, in-hospital, or surgery-related death, pooled at 7 percent. These figures place salvage esophagectomy firmly in the category of high-risk surgical oncology, comparable to the most demanding procedures performed today.

Yet the analysis also delivered a genuinely hopeful statistic: surgeons achieved an R0 resection—complete removal of the tumor with clear microscopic margins—in 72 percent of cases. This matters enormously because R0 status is the single strongest predictor of long-term survival in salvage surgery. In the included studies, five-year overall survival rates ranged widely, from as low as 5.7 percent to as high as 51.6 percent, depending on the institution and the completeness of resection. One study reported a five-year survival of 63.6 percent among patients who achieved R0 resection, compared with zero percent for those left with microscopic or gross residual disease. Another found that patients undergoing curative salvage surgery had a three-year survival of 58.7 percent, essentially matching the outcomes of patients whose tumors vanished completely with chemoradiotherapy alone.

The comparison with non-surgical outcomes is particularly sobering. In one Japanese series, patients who underwent salvage esophagectomy for T4 disease achieved a five-year overall survival of 51.6 percent, while those managed without surgery in the same cohort survived five years in only 1.3 percent of cases. This dramatic gap is the clinical argument for offering a procedure that carries a seven percent mortality risk: for a disease that is otherwise locally incurable, surgery may represent the only realistic path to long-term survival. The authors emphasize that when chemoradiotherapy fails locally—either leaving residual tumor or allowing relapse—salvage esophagectomy remains the only established strategy with the potential for cure.

Intriguingly, the pooled complication rates for these T4 patients were similar to those reported historically for salvage esophagectomy in earlier-stage disease, where morbidity rates of 50 to 79 percent and mortality rates of 6 to 22 percent have been documented. This suggests that pretreatment tumor depth may not dramatically alter surgical risk. Instead, the analysis revealed that institutional strategy—not the technology used—may be the decisive factor in pulmonary outcomes. One center that deliberately omitted prophylactic lymph node dissection and used open surgery reported a pneumonia rate of just 5.6 percent, while another performing standard two-field dissection with robotic assistance documented pulmonary complications in 54 percent of patients. The tension between oncological thoroughness and perioperative safety emerged as a central theme of the analysis.

Statistical heterogeneity was significant for both pulmonary complications and R0 resection rates, and sensitivity analyses pinpointed its sources. Excluding one study reduced the heterogeneity in pulmonary outcomes from 63 percent to 43 percent, implicating its unusual lymph node strategy. For R0 resection, heterogeneity fell when studies with a high proportion of relapsed tumors—rather than immediately residual disease—were removed. The authors note that surgery after relapse involves different pathological conditions and more treatment-induced fibrosis, which can obscure surgical planes and complicate complete resection. Even the definition of T4 disease varied: staging accuracy for CT and MRI has been reported at only 64 and 55 percent respectively, and diagnostic thresholds for declaring a tumor unresectable differed across centers, with some teams operating unless aortic or tracheal wall destruction was radiologically evident and others reserving surgery for tumors downstaged to T2 or below.

The authors are candid about the limitations of their work. All eight studies were case series vulnerable to selection bias, and publication bias may have inflated favorable outcomes—the Doi plots showed major asymmetry for pulmonary complications and R0 resection, indicated by LFK indices exceeding ±2. Survival meta-analysis was impossible due to inconsistent reporting, and mortality definitions were not standardized. Moreover, the results come largely from specialized esophageal centers in Japan, where surgeons may adopt more aggressive criteria for salvage candidacy than general institutions. These constraints mean the findings should be generalized with care, even as they affirm the procedure’s feasibility in expert hands.

What emerges from this synthesis is a nuanced picture of a discipline at its frontier. Salvage esophagectomy for T4 esophageal squamous cell carcinoma is a high-stakes intervention: roughly one in fourteen patients dies perioperatively, and nearly one in three suffers a major complication. But for the majority in whom a complete R0 resection can be achieved, the prospect of five-year survival exceeding 50 percent transforms a formerly fatal situation into a fight worth having. The authors call for standardized criteria for resectability and surgical extent, and they are conducting a nationwide survey through institutions accredited by the Japan Esophageal Society to gather more robust data. Given the rarity of eligible patients, randomized trials may never be practical—making carefully aggregated real-world evidence like this the compass that will guide surgeons and patients through one of cancer surgery’s most difficult decisions.

Subject of Research: Salvage esophagectomy for T4 esophageal squamous cell carcinoma after definitive chemoradiotherapy

Article Title: Systematic Review and Meta‐Analysis on the Efficacy and Safety of Salvage Esophagectomy for T4 Esophageal Squamous Cell Carcinoma

Article References: Sakai, M., Kuriyama, K., Nagai, K., Shirabe, K., & Saeki, H. (2026). Systematic Review and Meta‐Analysis on the Efficacy and Safety of Salvage Esophagectomy for T4 Esophageal Squamous Cell Carcinoma. Annals of Gastroenterological Surgery, 10(5), 1441-1449. https://doi.org/10.1002/ags3.70233

Image Credits: AI Generated

DOI: 10.1002/ags3.70233

Keywords: esophageal cancer, salvage esophagectomy, T4 esophageal squamous cell carcinoma, chemoradiotherapy, meta-analysis, R0 resection, anastomotic leak, postoperative complications, lymph node dissection, surgical oncology, Systematic, Review